Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by SCHEJA, A.
Right arrow Articles by ÀKESSON, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by SCHEJA, A.
Right arrow Articles by ÀKESSON, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1993 British Society for Rheumatology

brief-report

CARBOXYTERMINAL TYPE I PROCOLLAGEN PEPTIDE CONCENTRATIONS IN SYSTEMIC SCLEROSIS: HIGHER LEVELS IN EARLY DIFFUSE DISEASE

A. SCHEJA, G. HELLMER, F. A. WOLLHELM and A. ÀKESSON

Department of Rheumatology, University Hospital Lund, Sweden

Correspondence to: Correspondence to A. Scheja

Systemic sclerosis (SSc) is characterized by increased collagen deposition in skin and internal organs, and increased serum concentrations of different connective tissue metabolites have been reported. In this study serum concentrations of carboxyterminal type I (PICP) and aminoterminal type III procollagen peptide (PIIINP) were higher in 24 patients with diffuse cutaneous systemic sclerosis (dSSc), than in 30 patients with limited cutaneous systemic sclerosis (lSSc). Thirty patients with advanced and progressing disease had higher serum concentrations of both peptides than 24 patients with milder disease. In patients with advanced disease, both peptides showed a negative correlation to disease duration. Despite being relatively higher both in early, widespread and advanced disease, serum PICP concentrations varied only within the normal range for healthy controls. Thus PICP is of limited value as a marker of disease activity in SSc.

KEY WORDS: Procollagen peptide, Collagen, Aminoterminal type III procollagen peptide, Scleroderma


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 FASEB J.Home page
A. Akhmetshina, C. Dees, M. Pileckyte, B. Maurer, R. Axmann, A. Jungel, J. Zwerina, S. Gay, G. Schett, O. Distler, et al.
Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis
FASEB J, July 1, 2008; 22(7): 2214 - 2222.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
A. Scheja, M. Wildt, F. A. Wollheim, A. Akesson, and T. Saxne
Circulating collagen metabolites in systemic sclerosis. Differences between limited and diffuse form and relationship with pulmonary involvement
Rheumatology, October 1, 2000; 39(10): 1110 - 1113.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.